ABBV logo AbbVie +
AbbVie
+

AbbVie Overview

Company: AbbVie
CEO: Robert A. Michael
Founded: 2013
Symbol: ABBV
Exchange: NYSE
Industry: Drug Manufacturers - General
Sector: Healthcare
About

AbbVie is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading productslude HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie also engages in research collaborations,luding a partnership with Dragonfly Therapeutics The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

Continue reading...

AbbVie (ABBV)

  • Stock Price
  • Volume
248 +130.64 +111.32%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

AbbVie annual revenue was $61.16 B in 2025.

Net Income

AbbVie annual net income was $4.23 B in 2025.

Employees

AbbVie annual employee count was 57,000 in 2025.

Revenue by Segment

AbbVie’s revenue by segment: Alphagan/Combigan: $197.00 M, Botox Cosmetic: $2.60 B, Botox Therapeutic: $3.77 B, Duodopa: $381.00 M, H U M I R A: $4.54 B, Imbruvica: $2.87 B, Juvederm Collection: $993.00 M, Linzess/Constella: $907.00 M, Lumigan/Ganfort: $410.00 M, MAVYRET: $1.32 B, Other Aesthetics: $1.27 B, Other Eye Care: $1.01 B, Other Neuroscience: $207.00 M, Other Products: $2.63 B, Ozurdex: $493.00 M, Qulipta: $1.04 B, RINVOQ: $8.30 B, SKYRIZI: $17.56 B, Ubrelvy: $1.27 B, VENCLEXTA: $2.79 B and Vraylar: $3.62 B in 2025.

Revenue by Region

AbbVie’s revenue by region: Non-US: $2.36 B and UNITED STATES: $46.60 B in 2025.

Executive Salary

Robert A. Michael Chairman of the Board and Chief Executive Officer,...

Revenue per Employee

AbbVie revenue per employee was $1.07 M in 2025.

Profit per Employee

AbbVie profit per employee was $74.14 K in 2025.

Income Statement

Operating Income

AbbVie annual operating income was $21.21 B in 2025.

Research & Development

AbbVie annual research & development expense was $9.10 B in 2025.

Tax Rate (%)

AbbVie annual Tax Rate was 36.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

AbbVie annual total assets was $5.46 B in 2025.

Total Liabilities

AbbVie annual total liabilities was $26.29 B in 2025.

Capital Expenditure

AbbVie annual capital expenditures was - in 2025.

Ratios

Return on Equity (ROE)

AbbVie annual return on equity(ROE) was 0.00% in 2025.

Return on Assets (ROA)

AbbVie annual return on assets(ROA) was 0.00% in 2025.

Debt to Equity

AbbVie annual debt to equity was -2,112.17% in 2025.

Profitability

Gross Profit Margin (%)

AbbVie annual gross profit margin was 83.71% in 2025.

Operating Income Margin (%)

AbbVie annual operating income margin was 34.69% in 2025.

Net Income Margin (%)

AbbVie annual net income margin was 6.91% in 2025.

Earning Per Share

AbbVie annual earning per share was $2.37 in 2025.

EBITDA

AbbVie annual EBITDA was $28.29 B in 2025.

Free Cash Flow (FCF)

AbbVie annual free cash flow(FCF) was - in 2025.

Valuation

Enterprise value

AbbVie annual enterprise value was - in 2025.

Enterprise value to Revenue

AbbVie annual enterprise value to revenue was 0.00 in 2025.

Enterprise value to EBITDA

AbbVie annual enterprise value to EBITDA was 0.00 in 2025.

Competitors’ Revenue

Frequently Asked Questions

When was AbbVie founded?

AbbVie was founded on 2013, which makes the company 13 years old.

Sign up for free to view

Who is the CEO of AbbVie?

Robert A. Michael is the CEO of AbbVie.

What industry and sector is AbbVie in?

AbbVie operates in the Drug Manufacturers - General industry and the Healthcare sector.

What are AbbVie's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0001551152
  • SIC (Standard Industrial Classification): 2834
  • ISIN (International Securities Identification Number): US00287Y1091

Sign up for free to view

How many employees does AbbVie have?

AbbVie has 57,000 employees.

What is the revenue of AbbVie?

In fiscal year 2025, AbbVie generated a revenue of $61.16 Billion.

What is the net income of AbbVie?

In fiscal year 2025, AbbVie reported a net income of $4.23 Billion.

What is AbbVie's biggest product segment?

SKYRIZI is AbbVie's biggest product segment, representing 30.19% of its total revenue.

When was AbbVie listed on the stock exchange?

AbbVie went public on Jan 2, 2013, through its Initial Public Offering (IPO), and it has been 13 years since then.

Sign up for free to view

What is the ticker symbol of AbbVie, and where is it listed?

AbbVie's ticker symbol is ABBV, and the company is listed on the NYSE stock market exchange.

What is AbbVie's current stock price?

AbbVie's current stock price is $248.04 as of Jul 14, 2026.

What is AbbVie's market capitalization?

As of , AbbVie's market cap is .

What is AbbVie's ranking in the world?

Ranked #3among 2,804 companies based on market cap.

Who are the top competitors of AbbVie?

Competitors of AbbVie include Eli Lilly and Company, Johnson & Johnson and Merck & Co., and more.

People Also Search For

Submit feedback to Bullfincher